selective ER degrader (SERD) + full antagonist

oral (30 mg QD), Ph. III for ER+, HER2- BC

from profiling >4k cmpds for desired MoA

Journal of Medicinal Chemistry

Genentech, San Francisco, US

Chemical structure of Giredestrant

The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: